Cytosorbents Corp Cash Flow Statement
CTSO|8 years of annual SEC 10-K data (FY2011-FY2018)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Cytosorbents Corp used $11M in operating cash flow and negative free cash flow of $12M in FY2018.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -4.61 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$17.2M | -$8.5M | -$9.3M | -$9.5M | -$9.3M | -$5.3M | -$3.7M | -$5.5M |
| Depreciation & Amortization | $390.6K | $218.3K | $65.5K | $113.0K | $65.5K | $54.6K | $54.6K | $39.1K |
| Operating Cash Flow | -$10.8M | -$6.5M | -$6.3M | -$9.0M | -$6.7M | -$3.6M | -$3.6M | -$3.8M |
| Capital Expenditures | $672.0K | $990.7K | $153.2K | $403.6K | $153.2K | $19.9K | $19.9K | $34.7K |
| Free Cash Flow | -$11.5M | -$7.5M | -$6.4M | -$9.5M | -$6.8M | -$3.6M | -$3.6M | -$3.9M |
| FCF Margin | -233.8% | -49.2% | -156.1% | -197.3% | -165.3% | -270.8% | -270.8% | -10707.9% |